Net benefit separation and the determination curve: A probabilistic framework for cost-effectiveness estimation
暂无分享,去创建一个
Nicholas Illenberger | Nandita Mitra | Jason A. Roy | Andrew J. Spieker | J. Roy | N. Mitra | A. Spieker | N. Illenberger
[1] Chien-Chih Chen,et al. Real-world cost-effectiveness of laparoscopy versus open colectomy for colon cancer: a nationwide population-based study , 2017, Surgical Endoscopy.
[2] D. Lin,et al. Linear regression analysis of censored medical costs. , 2000, Biostatistics.
[3] Andrew Briggs,et al. Statistical Analysis of Cost-Effectiveness Data , 2006 .
[4] A J Moskowitz,et al. Bayesian estimation of cost-effectiveness ratios from clinical trials. , 1999, Health economics.
[5] J. Carroll,et al. Cost-Effectiveness of Patent Foramen Ovale Closure Versus Medical Therapy for Secondary Stroke Prevention , 2018, Stroke.
[6] D. Fan,et al. Cost-effectiveness analysis of fecal microbiota transplantation for inflammatory bowel disease , 2017, Oncotarget.
[7] J. Gold,et al. Validation of a combined comorbidity index. , 1994, Journal of clinical epidemiology.
[8] I. Nazareth,et al. Modelling the cost-effectiveness of preventing major depression in general practice patients , 2013, Psychological Medicine.
[9] D Polsky,et al. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. , 1997, Health economics.
[10] N. Zethraeus,et al. Definition, interpretation and calculation of cost-effectiveness acceptability curves. , 2000, Health economics.
[11] Arman Oganisian,et al. A causal approach to analysis of censored medical costs in the presence of time-varying treatment , 2017 .
[12] Elisabeth Fenwick,et al. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation , 2006, BMC Health Services Research.
[13] J. Jansen,et al. An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference? , 2018, Health policy.
[14] Nandita Mitra,et al. Propensity score and doubly robust methods for estimating the effect of treatment on censored cost , 2016, Statistics in medicine.
[15] A H Briggs,et al. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. , 1997, Health economics.
[16] M. Kaess,et al. A cost-effectiveness analysis of school-based suicide prevention programmes , 2018, European Child & Adolescent Psychiatry.
[17] Shihti Yu,et al. On the choice between sample selection and two-part models , 1996 .
[18] D. Mant. Prevention , 1994, The Lancet.
[19] M. Randall,et al. Adjuvant radiotherapy in endometrial carcinoma. , 2005, The oncologist.
[20] Andrew H Briggs,et al. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[21] A J Moskowitz,et al. Problems with Interval Estimates of the Incremental Cost—Effectiveness Ratio , 1999, Medical decision making : an international journal of the Society for Medical Decision Making.
[22] Nandita Mitra,et al. Analyzing medical costs with time‐dependent treatment: The nested g‐formula , 2018, Health economics.
[23] Daniel F Heitjan,et al. Bayesian estimation of cost‐effectiveness from censored data , 2004, Statistics in medicine.
[24] Anthony C. Davison,et al. Bootstrap Methods and Their Application , 1998 .
[25] Margaret S Pepe,et al. Using the ROC curve for gauging treatment effect in clinical trials , 2006, Statistics in medicine.
[26] Nandita Mitra,et al. A doubly robust approach for cost–effectiveness estimation from observational data , 2018, Statistical methods in medical research.
[27] Andrew Briggs,et al. Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions. , 2004, Health economics.
[28] Donald B. Rubin,et al. Bayesian Inference for Causal Effects: The Role of Randomization , 1978 .
[29] B. Delaney,et al. Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years: a randomised controlled trial in primary care , 2000, The Lancet.
[30] A R Willan,et al. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem. , 1996, Health economics.
[31] Andrew Briggs,et al. Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[32] A. Briggs,et al. Statistical Analysis of Cost-effectiveness Data: Willan/Statistical Analysis of Cost-effectiveness Data , 2006 .
[33] Jeffrey D Blume,et al. Measuring and illustrating statistical evidence in a cost-effectiveness analysis. , 2008, Journal of health economics.
[34] D. Heitjan,et al. EVALUATING COSTS WITH UNMEASURED CONFOUNDING: A SENSITIVITY ANALYSIS FOR THE TREATMENT EFFECT. , 2013, The annals of applied statistics.
[35] Michael M. Braun,et al. Diagnosis and Management of Endometrial Cancer. , 2016, American family physician.
[36] D.,et al. Regression Models and Life-Tables , 2022 .
[37] P. Scuffham,et al. Cost-effectiveness of home versus clinic-based management of chronic heart failure: Extended follow-up of a pragmatic, multicentre randomized trial cohort - The WHICH? study (Which Heart Failure Intervention Is Most Cost-Effective & Consumer Friendly in Reducing Hospital Care). , 2015, International journal of cardiology.
[38] Nobuyuki Susumu,et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. , 2008, Gynecologic oncology.
[39] J. Cavanaugh,et al. Partial Likelihood , 2018, Wiley StatsRef: Statistics Reference Online.